Cargando…
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
The clinical development of 4–1BB agonists for cancer immunotherapy has raised substantial interest during the past decade. The first generation of 4–1BB agonistic antibodies entering the clinic, urelumab (BMS-663513) and utomilumab (PF-05082566), failed due to (liver) toxicity or lack of efficacy,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897756/ https://www.ncbi.nlm.nih.gov/pubmed/36727218 http://dx.doi.org/10.1080/19420862.2023.2167189 |